The Guillain-Barré Syndromes

Peripheral Neuropathy

Volumn 2, Issue , 2005, Pages 2197-2219

  Griffin, John W ^a   Sheikh, Kazim ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247197390     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-9491-7.50101-0     Document Type: Chapter

References (217)

1. Ahmed S., Libman R., Wesson K., et al. Guillain-Barre syndrome: an unusual presentation of West Nile virus infection. Neurology 2000, 55:144.
2. Ali Z., Ringkamp M., Hartke T.V., et al. Uninjured C-fiber nociceptors develop spontaneous activity and alpha-adrenergic sensitivity following L6 spinal nerve ligation in the monkey. J. Neurophysiol. 1999, 81:455.
3. Allos B.M. Campylobacter jejuni infections: update on emerging issues and trends. Clin. Infect. Dis. 2001, 32:1201.
4. Ang C.W., de Klerk M.A., Endtz H.P., et al. Guillain-Barre syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b antibodies in rabbits. Infect. Immun. 2001, 69:2462.
5. Ang C.W., Laman J.D., Willison H.J., et al. Structure of Campylobacter jejuni lipopolysaccharides determines anti-ganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients. Infect. Immun. 2002, 70:1202.
6. Arasaki K., Kusunoki S., Kudo N., et al. The pattern of antiganglioside antibody reactivities producing myelinated nerve conduction block in vitro. J. Neurol. Sci. 1998, 161:163.
7. Asbury A.K., Arnason B.G., Adams R.D. The inflammatory lesion in idiopathic polyneuritis. Medicine 1969, 48:173.
8. Aspinall G.O., Fujimoto S., McDonald A.G., et al. Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barre syndrome patients mimic human gangliosides in structure. Infect. Immun. 1994, 62:2122.
9. Aspinall G.O., McDonald A.G., Pang H. Lipopoly-saccharides of Campylobacter jejuni serotype O: 19: structures of O antigen chains from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 1994, 33:250.
10. Aspinall G.O., McDonald A.G., Pang H., et al. Lipopoly-saccharides of Campylobacter jejuni serotype O: 19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 1994, 33:241.
11. Aspinall G.O., McDonald A.G., Raju T.S., et al. Chemical structures of the core regions of Campylobacter jejuni serotypes O: 1, O: 4, O: 23, and O: 36 lipopolysaccharides. Eur. J. Biochem. 1993, 213:1017.
12. Bauman M.B., DiMase J.D., Oski F., Senior J.R. Brown bowel and skeletal myopathy associated with vitamin E depletion in pancreatic insufficiency. Gastroenterology 1968, 54:93.
13. Berciano J., Garcia A. Nerve ischemia in Guillain-Barre syndrome: an alternative mechanism for early conduction failure. Rev. Neurol. (Paris) 2002, 158:364.
14. Black J.A., Dib-Hajj S., McNabola K., et al. Spinal sensory neurons express multiple sodium channel a-subunit mRNAs. Mol. Brain Res. 1996, 43:117.
15. + channel III and SNS gene expression in spinal sensory neurons. Neuroreport 1997, 8:2331.
16. Bowes T., Wagner E.R., Boffey J., et al. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barre syndrome. Infect. Immun. 2002, 70:5008.
17. Buchwald B., Toyka K.V., Zielasek J., et al. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barre syndrome: a macro-patch-clamp study. Ann. Neurol. 1998, 44:913.
18. Buchwald B., Weishaupt A., Toyka K.V., et al. Pre and postsynaptic blockade of neuromuscular transmission by Miller Fisher syndrome IgG at mouse motor nerve terminals. Eur. J. Neurosci. 1998, 10:281.
19. Carpo M., Pedotti R., Lolli F., et al. Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy. J. Neurol. Sci. 1998, 155:186.
20. Chiba A., Kusunoki S., Obata H., et al. Serum anti-GQ1b antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 1993, 43:1911.
21. Chiba A., Kusunoki S., Obata H., et al. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 1997, 745:32.
22. Cooke C.R., Latif K.A., Huch K.M., et al. Inappropriate antidiuresis and hyponatremia with suppressible vasopressin in Guillain-Barre syndrome. Am. J. Nephrol. 1998, 18:71.
23. Cornblath D.R., Griffin D.E., Welch D., et al. Quantitative analysis of endoneurial T-cells in human sural nerve biopsies. J. Neuroimmunol. 1990, 26:113.
24. Cornblath D.R., Mellits E.D., Griffin J.W., et al. Motor conduction studies in the Guillain-Barre syndrome: description and prognostic value. Ann. Neurol. 1988, 23:354.
25. Cummins T.R., Waxman S.G. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J. Neurosci. 1997, 17:3503.
26. De Angelis M.V, Di Muzio A., Lupo S., et al. Anti-GD1a antibodies from an acute motor axonal neuropathy patient selectively bind to motor nerve fiber nodes of Ranvier. J. Neuroimmunol. 2001, 121:79.
27. Dixon W.J. Efficient analysis of experimental observations. Annu. Rev. Pharmacol. Toxicol. 1980, 20:441.
28. Duménil L. Paralysie peripherique du mouvement et du sentiment, portant sur les quatre membres-atrophie des ramaux nerveux des parties paralysees. Gaz. Hebd. Med. Chir. 1864, 11:203.
29. Eames R., Gamble H. Schwann cell relationships in normal human cutaneous nerves. J. Anat. 1970, 106:417.
30. Eichhorst H. Neuritis acuta progressiva. Virchows Arch. 1877, 268.
31. Emilia-Romagna Study Group on Clinical and Epidemio-logical Problems in Neurology Campylobacter jejuni infection and Guillain-Barré syndrome: a case-control study. Neuroepidemiology 1998, 17:296.
32. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology Guillain-Barré syndrome variants in Emilia-Romagna, Italy, 1992-3: incidence, clinical features, and prognosis. J. Neurol. Neurosurg. Psychiatry 1998, 65:218.
33. Enders U., Karch H., Toyka K.V., et al. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barre syndrome and in other neuroimmunological disorders. Ann. Neurol. 1993, 34:136.
34. Feasby T.E., Gilbert J.J., Brown W.F., et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain 1986, 109:1115.
35. Feasby T.E., Hahn A.F., Brown W.F., et al. Severe axonal degeneration in acute Guillain-Barre syndrome: evidence of two different mechanisms?. J. Neurol. Sci. 1993, 116:185.
36. Figueras A., Morales-Olivas F.J., Capella D., et al. Bovine gangliosides and acute motor polyneuropathy. BMJ 1992, 305:1330.
37. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia ataxia and areflexia). N. Engl. J. Med. 1956, 255:57.
38. Fletcher D.D., Lawn N.D., Wolter T.D., et al. Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation. Neurology 2000, 54:2311.
39. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome Efficacy of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. Ann. Neurol. 1987, 22:753.
40. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome Plasma exchange in Guillain-Barre syndrome: one-year follow-up. Ann. Neurol. 1992, 32:94.
41. Friedman Y., Lee L., Wherrett J.R., et al. Simulation of brain death from fulminant de-efferentation. Can. J. Neurol. Sci. 2003, 30:397.
42. Fujimoto S., YGBRi N., Itoh T., et al. Specific serotype of Campylobacter jejuni associated with Guillain-Barre syndrome [letter]. J. Infect. Dis. 1992, 165:183.
43. Gabriel C.M., Gregson N.A., Hughes R.A. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J. Neuroimmunol. 2000, 104:139.
44. Ganser A.L., Kirschner D.A., Willinger M. Ganglioside localization on myelinated nerve fibres by cholera toxin binding. J. Neurocytol. 1983, 12:921.
45. Gombault Contribution a ľhistoire anatomique de ľatrophie musculaire saturnine. Arch. Physiol. 1873, V:592.
46. Gong Y., Tagawa Y., Lunn M.P., et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 2002, 125:2491.
47. Goodyear C.S., O'Hanlon G.M., Plomp J.J., et al. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J. Clin. Invest. 1999, 104:697. [published erratum appears in J. Clin. Invest. 104, 1771, 1999].
48. Granieri E., Casetta I., Govoni V., et al. Ganglioside therapy and Guillain-Barre syndrome: a historical cohort study in Ferrara, Italy, fails to demonstrate an association. Neuroepidemiology 1991, 10:161.
49. Grattan-Smith P.J., Morris J.G., Johnston H.M., et al. Clinical and neurophysiological features of tick paralysis. Brain 1997, 120:1975.
50. Graves R.J. Clinical Lectures on the Practice of Medicine. New Sydenham Soc. 1884, 1:578.
51. Greenwood R.J., Newsom-Davis J.M., Hughes R.A.C., et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984, 1:877.
52. Gregson N.A., Hammer C.T. Some immunological properties of antisera raised against the trisialoganglioside GT1B. Mol. Immunol. 1982, 19:543.
53. Gregson N.A., Koblar S., Hughes R.A.C. Antibodies to gangliosides in Guillain-Barre syndrome: specificity and relationship to clinical features. Q. J. Med. 1993, 86:111.
54. Griffin J.W., Li C.Y., Ho T.W., et al. Guillain-Barre syndrome in northern China: the spectrum of neuropathologic changes in clinically defined cases. Brain 1995, 118:577.
55. Griffin J.W., Li C.Y., Ho T.W., et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann. Neurol. 1996, 39:17.
56. Griffin J.W., Li C.Y., Macko C., et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barre syndrome. J. Neurocytol. 1996, 25:33.
57. Groher M.E. Dysphagic patients with progressive neurologic disease. Semin. Neurol. 1996, 16:355.
58. Guerry P., Szymanski C.M., Prendergast M.M., et al. Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro. Infect. Immun. 2002, 70:787.
59. Guillain G., Barré J.A., Strohl A. Sur un syndrome de radiculonebrite avec hyperalbuminose du liquide cephalorachidien sans reaction cellulaire: remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bull. Soc. Med. Hop. Paris 1916, 40:1462.
60. Guillain-Barre Study Group Plasmapheresis and acute Guillain-Barre syndrome. Neurology 1985, 35:1096.
61. Guillain-Barre Syndrome Steroid Trial Group Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 1993, 341:586.
62. Gupta S.K., Taly A.B., Suresh T.G., et al. Acute idiopathic axonal neuropathy (AIAN): a clinical and electrophysiological observation. Acta Neurol. Scand. 1994, 89:220.
63. Hadden R.D., Cornblath D.R., Hughes R.A., et al. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann. Neurol. 1998, 44:780.
64. Hadden R.D., Karch H., Hartung H.P., et al. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology 2001, 56:758.
65. Hadjivassiliou M., Gibson A., Davies-Jones G.A., et al. Does cryptic gluten sensitivity play a part in neurological illness? [see comments]. Lancet 1996, 347:369.
66. Hafer-Macko C., Hsieh S.-T., Li C.Y., et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann. Neurol. 1996, 40:635.
67. Hafer-Macko C., Sheikh K.A., Li C.Y., et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann. Neurol. 1996, 39:625.
68. Hagberg B. Polyneuropathies in paediatrics. Eur. J. Pediatr. 1990, 149:296.
69. Hahn A.F., Feasby T.E., Steele A., et al. Demyelination and axonal degeneration in Lewis rat experimental allergic neuritis depend on myelin dosage. Lab. Invest. 1988, 59:115.
70. 1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve 1995, 18:388.
71. Haymaker W., Kernohan J.W. The Landry-Guillain-Barre syndrome: a clinicopathologic report of fifty fatal cases and a critique of the literature. Medicine 1949, 28:59.
72. Hemachudha T., Phanuphak P., Johnson R.T., et al. Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies. Neurology 1987, 37:550.
73. Henderson R.D., Lawn N.D., Fletcher D.D., et al. The morbidity of Guillain-Barre syndrome admitted to the intensive care unit. Neurology 2003, 60:17.
74. Henderson R.D., Ohlrich G.D., Pender M.P. Guillain-Barre syndrome and optic neuritis after Mycoplasma pneumoniae infection. Aust. N. Z. J. Med. 1998, 28:481.
75. Hirota N., Kaji R., Bostock H., et al. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain 1997, 120:2159.
76. Ho T.W., Li C.Y., Cornblath D.R., et al. Patterns of recovery in the Guillain-Barré syndromes. Neurology 1997, 48:695.
77. Ho T.W., Hsieh S.-T., Nachamkin I., et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997, 48:717.
78. Ho T.W., Mishu B., Li C.Y., et al. Guillain-Barre syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995, 118:597.
79. Ho T.W., Willison H.J., Nachamkin I., et al. AntiGD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann. Neurol. 1999, 45:168.
80. Hochman M.S., Kobetz S.A., Handwerker J.V. Inappropriate secretion of antidiuretic hormone associated with Guillain-Barre syndrome. Ann. Neurol. 1982, 11:322.
81. Hoffmann O., Reuter U., Schielke E., et al. SIADH as the first symptom of Guillain-Barre syndrome. Neurology 1999, 53:1365.
82. Holmes G. Acute febrile polyneuritis. Br. Med. J. 1917, 2:37.
83. Honavar M., Tharakan J.K.J., Hughes R.A.C., et al. A clinicopathological study of the Guillain-Barre syndrome. Brain 1991, 114:1245.
84. Hughes R.A.C., Newsom-Davis J.M., Perkin G.D., et al. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978, 2:750.
85. Illa I., Ortiz N., Gallard E., et al. Acute axonal Guillain-Barre syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann. Neurol. 1995, 38:218.
86. Ilyas A.A., Cook S.D., Mithen F.A., et al. Antibodies to GT1a ganglioside in patients with Guillain-Barre syndrome. J. Neuroimmunol. 1998, 82:160.
87. Ilyas A.A., Willison H.J., Quarles R.H., et al. Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann. Neurol. 1988, 23:440.
88. Jacobs B.C., Endtz H., van der Meché F.G.A., et al. Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann. Neurol. 1995, 37:260.
89. Jacobs B.C., Hazenberg M.P., Van Doorn P.A., et al. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J. Infect. Dis. 1997, 175:729.
90. Jacobs B.C., Van Doorn P.A., Schmitz P.I., et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann. Neurol. 1996, 40:181.
91. Jampel R.S., Haidt S.J. Bell's phenomenon and acute idiopathic polyneuritis. Am. J. Ophthalmol. 1972, 74:145.
92. Jeha L.E., Sila C.A., Lederman R.J., et al. West Nile virus infection: a new acute paralytic illness. Neurology 2003, 61:55.
93. Kanda T., Yamawaki M., Mizusawa H. Sera from Guillain-Barre patients enhance leakage in blood-nerve barrier model. Neurology 2003, 60:301.
94. Kashihara K., Shiro Y., Koga M., et al. IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry 1998, 65:799.
95. 2 myelin proteins in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J. Neuroimmunol. 1993, 46:245.
96. Kikuchi M., Tagawa Y., Iwamoto H., et al. Bickerstaff's brainstem encephalitis associated with IgG anti-GQ1b antibody subsequent to Mycoplasma pneumoniae infection: favorable response to immunoadsorption therapy. J. Child Neurol. 1997, 12:403.
97. Koga M., Tatsumoto M., YGBRi N., et al. Range of cross reactivity of anti-GM1 IgG antibody in Guillain-Barre syndrome. J. Neurol. Neurosurg. Psychiatry 2001, 71:123.
98. Koga M., YGBRi N., Ariga T., et al. Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome?. J. Neuroimmunol. 1998, 86:74.
99. Koga M., YGBRi N., Takahashi M., et al. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barre and Fisher's syndromes. J. Neuroimmunol. 1998, 81:138.
100. Kornberg A.J., Pestronk A., Blume G.M., et al. Selective staining of the cerebellar molecular layer by serum IgG in Miller-Fisher and related syndromes. Neurology 1996, 47:1317.
101. Kuroki S., Saida T., NGBRina M., et al. Campylobacter jejuni strains from patients with Guillain-Barre syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. Ann. Neurol. 1993, 33:243.
102. Kusunoki S., Chiba A., Kon K., et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barre syndrome. Ann. Neurol. 1994, 35:570.
103. Kusunoki S., Hitoshi S., Kaida K., et al. Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. Ann. Neurol 1999, 45:400.
104. Kusunoki S., Iwamori M., Chiba A., et al. GM1b is a new member of antigen for serum antibody in Guillain-Barré syndrome. Neurology 1996, 47:237.
105. Kusunoki S., Mashiko H., MochizGBRi N., et al. Binding of antibodies against GM1 and GD1b in human peripheral nerve. Muscle Nerve 1997, 20:840.
106. Kusunoki S., Shimizu J., Chiba A., et al. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann. Neurol. 1996, 39:424.
107. Kuwabara S., Asahina M., Koga M., et al. Two patterns of clinical recovery in Guillain-Barre syndrome with IgG anti-GM1 antibody. Neurology 1998, 51:1656.
108. 0 in inflammatory neuropathies. J. Neuroimmunol. 2001, 116:220.
109. Landry O. Note sur paralysie ascendante aiguë. Gaz. Hebd. Med. Chir. 1859, 7:472.
110. Lastovica A.J., Goddard E.A., Argent A.C. Guillain-Barre syndrome in South Africa associated with Campylobacter jejuni O: 41 strains. J. Infect. Dis. 1997, 176(Suppl. 2):S139.
111. Lawn N.D., Fletcher D.D., Henderson R.D., et al. Anticipating mechanical ventilation in Guillain-Barre syndrome. Arch. Neurol. 2001, 58:893.
112. Leyden E. Ueber einen Fall von multipler Neuritis. Charite Annal. 1880, 206.
113. Li C.Y., Xue P., Gao C.Y., et al. Experimental Campylobacter jejuni infection in the chicken: an animal model of axonal Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry 1996, 61:279.
114. Lichtenfeld P. Autonomic dysfunction in the Guillain-Barre syndrome. Am. J. Med. 1971, 50:772.
115. 1 antibodies: comparative characterization of experimentally induced vs. disease-associated antibodies. J. Neuroimmunol. 2002, 128:69.
116. Lugaresi A., Uncini A., Torrieri F., et al. Acute motor axonal neuropathy with high titer IgG and IgA anti-GD1a antibodies following Campylobacter enteritis. J. Neurol. Sci. 1997, 147:193.
117. Lunn M.P., Johnson L.A., Fromholt S.E., et al. High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: reexamination of GD1a immunolocalization. J. Neurochem. 2000, 75:404.
118. Maehara T., Ono K., Tsutsui K., et al. A monoclonal antibody that recognizes ganglioside GD1b in the rat central nervous system. Neurosci. Res. 1997, 29:9.
119. Massaro M.E., Rodriguez E.C., Pociecha J., et al. Nerve biopsy in children with severe Guillain-Barre syndrome and inexcitable motor nerves. Neurology 1998, 51:394.
120. McKhann G.M., Cornblath D.R., Griffin J.W., et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann. Neurol. 1993, 33:333.
121. McKhann G.M., Cornblath D.R., Ho T.W., et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991, 338:593.
122. McKhann G.M., Griffin J.W., Cornblath D.R., et al. Plasmapheresis and Guillain-Barre syndrome. I. Factors influencing outcome. Neurology 1987, 37(Suppl.):252.
123. McKhann G.M., Griffin J.W., Cornblath D.R., et al. Plasmapheresis and Guillain-Barre syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann. Neurol. 1988, 23:347.
124. Mendell J.R., Kissel J.T., Kennedy M.S., et al. Plasma exchange and prednisone in Guillain-Barre syndrome: a controlled randomized trial. Neurology 1985, 35:1551.
125. Mishu B., Ilyas A.A., Koski C.L., et al. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barre syndrome. Ann. Intern. Med. 1993, 118:947.
126. Mizoguchi K., Hase A., Obi T., et al. Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J. Neurol. Neurosurg. Psychiatry 1994, 57:1121.
127. Moran A.P., Penner J.L. Serotyping of Campylobacter jejuni based on heat-stable antigens: relevance, molecular basis and implications in pathogenesis. J. Appl. Microbiol. 1999, 86:361.
128. Moran A.P., Prendergast M.M., Hogan E.L. Sialosyl-galactose: a common denominator of Guillain-Barré and related disorders?. J. Neurol. Sci. 2002, 196:1.
129. Nachamkin I., Engberg J., Gutacker M., et al. Molecular population genetic analysis of Campylobacter jejuni HS: 19 associated with Guillain-Barre syndrome and gastroenteritis. J. Infect. Dis. 2001, 184:221.
130. Nachamkin I., Ung H., Moran A.P., et al. Ganglioside GM1 mimicry in Campylobacter strains from sporadic infections in the United States. J. Infect. Dis. 1999, 179:1183. [Published erratum appears in J. Infect. Dis.179, 1593, 1999.].
131. Nadkarni N., Lisak R.P. Guillain-Barre syndrome (GBS) with bilateral optic neuritis and central white matter disease. Neurology 1993, 43:842.
132. Nagai Y., Momoi T., Saito M., et al. Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides. Neurosci. Lett. 1976, 2:107.
133. Neisser A., Bernheimer H., Berger T., et al. Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller Fisher syndrome. Infect. Immun. 1997, 65:4038.
134. Neisser A., Schwerer B., Bernheimer H., et al. Ganglioside-induced antiganglioside antibodies from a neuropathy patient cross-react with lipopolysaccharides of Campylobacter jejuni associated with Guillain-Barre syndrome. J. Neuroimmunol. 2000, 102:85.
135. O'Hanlon G.M., Paterson G.J., Veitch J., et al. Mapping immunoreactive epitopes in the human peripheral nervous system using human anti-GM1 ganglioside antibodies. Acta Neuropathol 1998, 95:605.
136. O'Hanlon G.M., Paterson G.J., Wilson G., et al. Anti-GM1 ganglioside antibodies cloned from autoimmune neuropathy patients show diverse binding patterns in the rodent nervous system. J. Neuropathol. Exp. Neurol. 1996, 55:184.
137. O'Leary C.P., Veitch J., Durward W.F., et al. Acute oropha-ryngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J. Neurol. Neurosurg. Psychiatry 1996, 61:649.
138. O'Leary C.P., Willison H.J. Autoimmune ataxic neuropathies (sensory ganglionopathies). Curr. Opin. Neurol. 1997, 10:366.
139. Odaka M., YGBRi N., Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J. Neurol. Neurosurg. Psychiatry 2001, 70:50.
140. Odaka M., YGBRi N., Yamada M., et al. Bickerstaff's brain-stem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 2003, 126:2279.
141. Ogawa-Goto K., Funamoto N., Abe T., et al. Different ceramide compositions of gangliosides between human motor and sensory nerves. J. Neurochem. 1990, 55:1486.
142. Ogawara K., Kuwabara S., Mori M., et al. Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann. Neurol. 2000, 48:624.
143. Ogino M., Orazio N., Latov N. IgG anti-GM1 antibodies from patients with acute motor neuropathy are predominantly of the IgG1 and IgG3 subclasses. J. Neuroimmunol. 1995, 58:77.
144. Oomes P.G., Jacobs B.C., Hazenberg M.P.H., et al. Anti-GM1 IgG antibodies and Campylobacter jejuni bacteria in Guillain-Barre syndrome: evidence of molecular mimicry. Ann. Neurol. 1995, 38:170.
145. Osler W. The Principles and Practice of Medicine 1892, Appleton, New York.
146. Osterman P.O., Lundemo G., Pirskanen R., et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984, 2:1296.
147. Paparounas K., O'Hanlon G.M., O'Leary C.P., et al. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro [see comments]. Brain 1999, 122:807. Pt. 5.
148. Perkin G.D., Murray-Lyon I. Neurology and the gastrointestinal system. J. Neurol. Neurosurg. Psychiatry 1998, 65:291.
149. Pestronk A., Choksi R., Yee W.C., et al. Serum antibodies to heparan sulfate glycosaminoglycans in Guillain-Barré syndrome and other demyelinating polyneuropathies. J. Neuroimmunol. 1998, 91:204.
150. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997, 349:225.
151. Plomp J.J., Molenaar P.C., O'Hanlon G.M., et al. Miller Fisher anti-GQ1b antibodies: a-latrotoxin-like effects on motor end plates. Ann. Neurol. 1999, 45:189. [Published erratum appears in Ann. Neurol. 45, 823, 1999.].
152. Prendergast M.M., Lastovica A.J., Moran A.P. Lipopolysaccharides from Campylobacter jejuni O: 41 strains associated with Guillain-Barre syndrome exhibit mimicry of GM1 ganglioside. Infect. Immun. 1998, 66:3649.
153. Prendergast M.M., Moran A.P. Lipopolysaccharides in the development of the Guillain-Barre syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. J. Endotoxin Res. 2000, 6:342.
154. Prendergast M.M., Willison H.J., Moran A.P. Human monoclonal immunoglobulin M antibodies to ganglioside GM1 show diverse cross-reactivities with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain-Barre syndrome. Infect. Immun. 1999, 67:3698.
155. Prineas J.W. Acute idiopathic polyneuritis: an electron microscope study. Lab. Invest. 1972, 26:133.
156. Raine C.S., Wisniewski H., Prineas J. An ultrastructural study of experimental demyelination and remyelination. Lab. Invest. 1969, 21:316.
157. Ramos-Alvarez M., Bessudo L., Sabin A. Paralytic syndromes associated with noninflammatory cytoplasmic or nuclear neuronopathy: acute paralytic disease in Mexican children, neuropathologically distinguishable from Landry-Guillain-Barre syndrome. JAMA 1969, 207:1481.
158. Raschetti R., Maggini M., Popoli P., et al. Gangliosides and Guillain-Barre syndrome. J. Clin. Epidemiol. 1995, 48:1399.
159. Ravn H. The Landry-Guillain-Barre syndrome. Acta Neurol. Scand. 1967, 30:8.
160. Rees J.H., Gregson N.A., Hughes R.A.C. Anti-ganglioside GM1 antibodies in Guillain-Barre syndrome and their relationship to Campylobacter jejuni infection. Ann. Neurol. 1995, 38:809.
161. Rees J.H., Soudain S.E., Gregson N.A., et al. Campylobacter jejuni infection and Guillain-Barré syndrome. N. Engl. J. Med. 1995, 333:1374.
162. Reisin R.C., Cersosimo R., Garcia Alvarez M., et al. Acute "axonal" Guillain-Barre syndrome in childhood. Muscle Nerve 1993, 16:1310.
163. Rhodes K.M., Tattersfield A.E. Guillain-Barre syndrome associated with Campylobacter infection. Br. Med. J.(Clin. Res. Ed.) 1982, 285:173.
164. Roberts M., Willison H.J., Vincent A., et al. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann. Neurol. 1995, 38:111.
165. Ropper A.H. Miller Fisher syndrome and other acute variants of Guillain-Barre syndrome. Baillieres Clin. Neurol. 1994, 3:95.
166. Ropper A.H., Kehne S.M. Guillain-Barre syndrome: management of respiratory failure. Neurology 1985, 35:1662.
167. Ropper A.H., Shahani B.T. Diagnosis and management of acute areflexic paralysis with emphasis on Guillain-Barre syndrome. Peripheral Nerve Disorders: A Practical Approach 1984, 21. Butterworths, London. A.K. Asbury, R.W. Gilliatt (Eds.).
168. Ross J., Bury J.S. A Treatise on Peripheral Neuritis 1893, Charles Griffin, London.
169. Saez-Torres I., Diaz-Villoslada P., Martinez-Caceres E., et al. Gangliosides do not elicit experimental autoimmune encephalomyelitis in Lewis rats and SJL mice. J. Neuro-immunol. 1998, 84:24-29.
170. Saleh M.N., Khazaeli M.B., Wheeler R.H., et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res. 1992, 52:4342-4347.
171. Salloway S., Mermel L.A., Seamans M., et al. Miller-Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. Infect. Immun. 1996, 64:2945.
172. Schonhofer P.S. Guillain-Barre syndrome and parenteral gangliosides. Lancet 1991, 338:757.
173. Schwerer B., Neisser A., Bernheimer H. Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection. Infect. Immun. 1999, 67:2414.
174. Sheikh K.A., Deerinck T.J., Ellisman M.H., et al. The distribution of ganglioside-like moieties in peripheral nerves. Brain 1999, 122:449. Pt. 3.
175. Sheikh K.A., Ho T.W., Nachamkin I., et al. Molecular mimicry in Guillain-Barré syndrome. Ann. N. Y. Acad. Sci. 1998, 845:307.
176. Sheikh K.A., Nachamkin I., Ho T.W., et al. Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome: molecular mimicry and host susceptibility. Neurology 1998, 51:371.
177. Shen K.F., Crain S.M. Nerve growth factor rapidly prolongs the action potential of mature sensory ganglion neurons in culture and this effect requires activation of Gs coupled excitatory kappa opioid receptors on these cells. J. Neurosci. 1994, 14:5570.
178. Shin J.E., Ackloo S., Mainkar A.S., et al. Lipo-oligosaccharides of Campylobacter jejuni serotype O: 10: structures of core oligosaccharide regions from a bacterial isolate from a patient with the Miller-Fisher syndrome and from the serotype reference strain. Carbohydr. Res. 1997, 305:223.
179. Stojkovic T., Verdin M., Hurtevent J.F., et al. Guillain-Barre syndrome resembling brainstem death in a patient with brain injury. J. Neurol. 2001, 248:430.
180. SusGBRi K., YGBRi N., Hirata K., et al. Fine specificities of anti-LM1 IgG antibodies in Guillain-Barre syndrome. J. Neurol. Sci. 2002, 195:145.
181. Svennerholm L., Bostrom K., Fredman P., et al. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim. Biophys. Acta 1994, 1214:115.
182. Tagawa Y, YGBRi N., Hirata K. High anti-GM1 and anti-GD1a IgG antibody titers are detected in Guillain-Barre syndrome but not in chronic inflammatory demyelinating polyneuropathy. Eur. Neurol. 2002, 48:118.
183. + currents in isolated rat myelinated nerve fibers. Ann. Neurol. 1995, 37:436.
184. ter Bruggen J.P., van der Meche F.G., de Jager A.E., et al. Ophthalmoplegic and lower cranial nerve variants merge into each other and into classical Guillain-Barré syndrome. Muscle Nerve 1998, 21:239.
185. Trojaborg W. Acute and chronic neuropathies: new aspects of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, an overview and an update. Electroencephalogr. Clin. Neurophysiol. 1998, 107:303.
186. van der Meché F.G.A., Schmitz P.I.M., for the Dutch Guillain-Barre Study Group A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N. Engl. J. Med. 1992, 326:1123.
187. vanKoningsveld R., Schmitz P.I.M., van der Meche F.G.A., et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 2004, 363:192.
188. Vargas F., Hilbert G., Gruson D., et al. Fulminant Guillain-Barre syndrome mimicking cerebral death: case report and literature review. Intensive Care Med. 2000, 26:623.
189. Visser L.H., van der Meché F.G.A., Meulstee J., et al. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Neurology 1996, 47:668.
190. Vriesendorp F.J., Mishu B., Blaser M., et al. Serum antibodies to GM1, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barre syndrome and controls: correlation and prognosis. Ann. Neurol. 1993, 34:130.
191. Waller A. Experiments on the section of glossopharyngeal and hypoglossal nerves of the frog and observations of the alternatives produced thereby in the structure of their primitive fibers. Philos. Trans. R. Soc. Lond. 1850, 140:423.
192. Walsh F.S., Cronin M., Koblar S., et al. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barre syndrome. J. Neuroimmunol. 1991, 34:43.
193. Weber F., Rudel R., Aulkemeyer P., et al. Anti-GM1 antibodies can block neuronal voltage-gated sodium channels. Muscle Nerve 2000, 23:1414.
194. Willison H.J., Almemar A., Veitch J., et al. Acute ataxic neuropathy with cross-reactive antibodies to GD1b and GD3 gangliosides. Neurology 1994, 44:2395.
195. Willison H.J., O'Hanlon G.M., Paterson G., et al. A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. J. Clin. Invest. 1996, 97:1155.
196. Willison H.J., Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J. Neuroimmunol. 1994, 50:159.
197. Willison H.J., Veitch J., Paterson G., Kennedy P.G. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J. Neurol. Neurosurg. Psychiatry 1993, 56:204.
198. Winer J.B., Hughes R.A.C., Osmond C. A prospective study of acute idiopathic neuropathy. 1. Clinical features and their prognostic value. J. Neurol. Neurosurg. Psychiatry 1988, 51:605.
199. Winer J.B., Hughes R.A.C., Osmond C. A prospective study of acute idiopathic neuropathy. 3. Immunological studies. J. Neurol. Neurosurg. Psychiatry 1988, 51:619.
200. Wirguin I., Briani C., Suturkova-Milosevic L., et al. Induction of anti-GM1 ganglioside antibodies by Campylobacter jejuni lipopolysaccharides. J. Neuroimmunol. 1997, 78:138.
201. Wirguin I., Suturkova-Milosevic L., Della-Latta P., et al. Monoclonal IgM antibodies to GM1 and asialo-GM1 in chronic neuropathies cross-react with Campylobacter jejuni lipopolysaccharides. Ann. Neurol. 1994, 35:698.
202. Wu H.-S., Liu T.C., Lu Z.L., et al. A prospective clinical and electrophysiologic survey of acute flaccid paralysis in Chinese children. Neurology 1997, 49:1723.
203. Yoshino H. Distribution of gangliosides in the nervous tissues recognized by axonal form of Guillain-Barre syndrome [in Japanese]. Neuroimmunology 1997, 5:174.
204. YGBRi N. Successful plasmapheresis in Bickerstaff's brain stem encephalitis associated with anti-GQ1b antibody. J. Neurol. Sci. 1995, 131:108.
205. YGBRi N., Handa S., Tai T., et al. Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain-Barre syndrome. J. Neurol. Sci. 1995, 130:112.
206. YGBRi N., Ichihashi Y., Taki T. Subclass of IgG antibody to GM1 epitope-bearing lipopolysaccharide of Campylobacter jejuni in patients with Guillain-Barre syndrome. J. Neuroimmunol. 1995, 60:161.
207. YGBRi N., Sato S., Fujimoto S., et al. Serotype of Campylobacter jejuni, HLA, and the Guillain-Barre syndrome. Muscle Nerve 1992, 16:968.
208. YGBRi N., Sato S., Tsuji S., et al. Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Neurology 1993, 43:414.
209. YGBRi N., Sato S., Tsuji S., et al. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J. Neurol. Sci. 1993, 118:83.
210. YGBRi N., Taki T., Inagaki F., et al. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J. Exp. Med. 1993, 178:1771.
211. 1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann. Neurol. 1994, 36:791.
212. YGBRi N., Yamada M., Koga M., et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann. Neurol. 2001, 49:712.
213. YGBRi N., Yamada M., Sato S., et al. Association of IgG anti-GD1a antibody with severe Guillain-Barre syndrome. Muscle Nerve 1993, 16:642.
214. YGBRi N., Yamada M., Tagawa Y., et al. Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J. Neurol. Sci. 1997, 149:127.
215. 1 antibodies following Campylobacter jejuni enteritis. Neurology 1990, 40:1900.
216. 1a antibodies. Muscle Nerve 1992, 15:899.
217. Zhang G., Lopez P.H., Li C.Y., et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004, 127:1085. Pt. 5.